Annual report pursuant to Section 13 and 15(d)

Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)

v3.24.0.1
Revenue - Collaboration Agreement - The GSK Termination and Transfer Agreement (Details)
 1 Months Ended 12 Months Ended
Dec. 31, 2023
GBP (£)
Sep. 30, 2023
GBP (£)
Jun. 30, 2023
GBP (£)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
GBP (£)
Dec. 31, 2022
USD ($)
Apr. 06, 2023
USD ($)
Apr. 06, 2023
GBP (£)
Revenue                
Revenue recognized in the period       $ 59,072,000   $ 17,648,000    
GSK Termination and Transfer Agreement                
Revenue                
Upfront payment received | £     £ 7,500,000          
Milestone payment | £ £ 12,000,000 £ 3,000,000            
Potential milestone payments to be received | £         £ 7,500,000      
Amount of transaction price of the agreement at inception             $ 37,335,000  
Upfront and milestone payment receivable | £               £ 30,000,000
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements       37,562,000        
IGNYTE                
Revenue                
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements       20,903,000        
LTFU                
Revenue                
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements       $ 16,659,000